JP2013533287A - 嗅覚機能不全の処置のためのラサギリンの使用 - Google Patents

嗅覚機能不全の処置のためのラサギリンの使用 Download PDF

Info

Publication number
JP2013533287A
JP2013533287A JP2013521949A JP2013521949A JP2013533287A JP 2013533287 A JP2013533287 A JP 2013533287A JP 2013521949 A JP2013521949 A JP 2013521949A JP 2013521949 A JP2013521949 A JP 2013521949A JP 2013533287 A JP2013533287 A JP 2013533287A
Authority
JP
Japan
Prior art keywords
olfactory
subject
pharmaceutically acceptable
acceptable salt
propargyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013521949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533287A5 (enExample
Inventor
ペティ、ゲラルディン
ブルンディン、パトリック
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2013533287A publication Critical patent/JP2013533287A/ja
Publication of JP2013533287A5 publication Critical patent/JP2013533287A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2013521949A 2010-07-27 2011-07-27 嗅覚機能不全の処置のためのラサギリンの使用 Ceased JP2013533287A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40046410P 2010-07-27 2010-07-27
US61/400,464 2010-07-27
US201161437212P 2011-01-28 2011-01-28
US61/437,212 2011-01-28
PCT/US2011/045574 WO2012015950A1 (en) 2010-07-27 2011-07-27 Use of rasagiline for the treatment of olfactory dysfunction

Publications (2)

Publication Number Publication Date
JP2013533287A true JP2013533287A (ja) 2013-08-22
JP2013533287A5 JP2013533287A5 (enExample) 2014-10-16

Family

ID=45527351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013521949A Ceased JP2013533287A (ja) 2010-07-27 2011-07-27 嗅覚機能不全の処置のためのラサギリンの使用

Country Status (7)

Country Link
US (1) US8569379B2 (enExample)
EP (1) EP2603212A4 (enExample)
JP (1) JP2013533287A (enExample)
AU (1) AU2011282720B2 (enExample)
CA (1) CA2806740A1 (enExample)
RU (1) RU2587330C2 (enExample)
WO (1) WO2012015950A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2643235C (en) * 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
DK2101569T3 (da) * 2006-12-14 2012-01-30 Teva Pharma Krystallinsk fast rasagilinbase
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CN101909438A (zh) * 2008-01-11 2010-12-08 泰华制药工业有限公司 雷沙吉兰制剂、其制备及用途
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
WO2011087791A1 (en) * 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
KR20140090996A (ko) 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
EA201490760A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. R(+)-n-метилпропаргиламиноиндан
MX2015002062A (es) 2012-08-17 2015-06-05 Teva Pharma Formulaciones parenterales de rasagilina.
RU2713786C1 (ru) * 2019-05-24 2020-02-07 Сергей Геннадиевич Вахрушев Способ лечения пациентов с обонятельной дисфункцией при атрофическом рините

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151625A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline for parkinson's disease modification

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL112819A (en) 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
ATE292619T1 (de) 1996-12-18 2005-04-15 Teva Pharma Aminoindanderivate
US7326690B2 (en) 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
ES2588780T3 (es) 2002-11-15 2016-11-04 Teva Pharmaceutical Industries Limited Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica
EP1730122A2 (en) * 2004-03-30 2006-12-13 Taisho Pharmaceutical Co., Ltd Pyrimidine derivatives and methods of treatment related to the use thereof
CA2574925A1 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
JP5738509B2 (ja) 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド 内容物均一性が改善されたラサギリン製剤
CN101622225B (zh) 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
CA2643235C (en) 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
BRPI0718339A2 (pt) 2006-12-14 2014-02-18 Teva Pharma Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
DK2101569T3 (da) 2006-12-14 2012-01-30 Teva Pharma Krystallinsk fast rasagilinbase
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
WO2009003147A1 (en) 2007-06-26 2008-12-31 Parkinson's Institute Methods and compositions for the treatment of neurological disorders
EP2194780A4 (en) 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CN101909438A (zh) 2008-01-11 2010-12-08 泰华制药工业有限公司 雷沙吉兰制剂、其制备及用途
US20100008983A1 (en) 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
EP2299993A4 (en) 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
CA2727017A1 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for preparing and drying solid rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
JP2013507352A (ja) 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
WO2011087791A1 (en) 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
KR20140023872A (ko) 2010-10-26 2014-02-27 테바 파마슈티컬 인더스트리즈 리미티드 중수소 농축 라사길린

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151625A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline for parkinson's disease modification

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015024065; Ａｌｖａｒｅｚ，　Ｍ．　Ｖ．　ｅｔ　ａｌ．，　Ｍｏｖｅｍｅｎｔ　Ｄｉｓｏｒｄｅｒｓ，　２０１０，　Ｖｏｌ．２５，　Ｓｕｐｐ．　２，　ｐ．　Ｓ２５５，　Ａｂｓｔｒａｃｔ　Ｎｕｍｂｅｒ：２１１ *
JPN6015024066; Ｓｉｍｕｎｉ，　Ｔ．　ｅｔ　ａｌ．，　Ｅｕｒｏｐｅａｎ　Ｎｅｕｒｏｌｏｇｙ，　２００９，　Ｖｏｌ．６１，　Ｎｏ．４，　ｐ．２０６-２１５ *

Also Published As

Publication number Publication date
RU2013108258A (ru) 2014-09-10
AU2011282720A1 (en) 2013-03-14
US20120029087A1 (en) 2012-02-02
WO2012015950A1 (en) 2012-02-02
RU2587330C2 (ru) 2016-06-20
US8569379B2 (en) 2013-10-29
AU2011282720B2 (en) 2016-12-22
EP2603212A1 (en) 2013-06-19
EP2603212A4 (en) 2014-01-08
CA2806740A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
JP2013533287A (ja) 嗅覚機能不全の処置のためのラサギリンの使用
Hare et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures
CN100450475C (zh) 用于治疗注意力缺陷多动障碍及多发性硬化症疲劳的含有莫达非尼的组合物
JP5701485B2 (ja) 多系統萎縮症の治療のためのラサギリンの使用
CN101442997B (zh) 雷沙吉兰用于治疗多动腿综合征
US9980927B2 (en) Use of tapentadol for inhibiting and/or treating depression and anxiety
JP6668045B2 (ja) ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
US20230310368A1 (en) Mdma enantiomers
US20250090637A1 (en) Methods of inhibiting cerebral inflammation
WO2010132128A1 (en) Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease
US20230226019A1 (en) Mdma enantiomers
JP7744419B2 (ja) レット症候群を治療するためのプリドピジンまたはその類似体の使用
CN117396200A (zh) 辅助性d-环丝氨酸对重度抑郁症的经颅磁刺激（tms）治疗的增效作用
WO2012136351A1 (en) Tapentadol for treating pain associated with trigeminal neuralgia
CN115337307A (zh) 布托啡诺或其盐在制备抗抑郁药物中的新用途
Zare et al. Wake-Promoting agents; insights into clinical use and molecular perspectives
WO2024196772A2 (en) Mdma enantiomers
CA2575204A1 (en) Methods of treating ophthalmic conditions
WO2024253775A1 (en) Mdma enantiomers
US20190274974A1 (en) Treatment of Pain Associated with Trigeminal Neuralgia
JP2022521579A (ja) ピット・ホプキンス症候群の治療
Woodlee Mechanisms underlying the dysregulation of postural stability in dopamine-depleted rats

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160531

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20180227